FTER, BLDV, PWRM, CVIT, SSEV, VG OTCPicks.com Stocks to Watch for Thursday, September 3rd

Our Stocks to Watch tomorrow include Forterus Inc. (OTC: FTER), Blue Diamond Ventures Inc. (OTC: BLDV), Power3 Medical Products Inc. (OTCBB: PWRM), Cavit Sciences Inc. (OTC: CVIT), Systems Evolution Inc. (OTC: SSEV) and Vonage Holdings Corp. (NYSE: VG).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

FORTERUS INCORPORATED (OTC: FTER)

"Up 77.42% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/FTER.php

Forterus, Inc. provides various healthcare services for people who need help from addictions, including gambling, misuse of prescription painkillers, drug, and alcohol abuse. The company provides a 28 to 90 day treatment program, which includes behavioral healthcare, drug and alcohol rehabilitation, pain management, and physical therapy. It has facilities in Murrieta, California (‘A Better Tomorrow’) and Dana Point, California. The company also offers a separate treatment program for adolescents and Spanish-language services. The company was formerly known as Mezey Howarth Racing Stables, Inc. and changed its name to Forterus, Inc. in July 2008. Forterus, Inc. was founded in 2007 and is based in Huntington Beach, California.

FTER News:

September 2 - Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed

Forterus Inc. (OTC: FTER), which, through its ABTTC Inc. division, provides drug and alcohol rehabilitation and a variety of other behavioral healthcare services with the highest levels of accreditation, announced today that its co-founder and CEO, Paul Howarth, was interviewed by analyst Francis Gaskin on the Company's recent successes, management team and shareholder relations.

The complete interview is available at www.stoxrox.com/fter-9-1-09-voice.mp3.

"We are becoming one of the largest drug and alcohol rehabilitation and treatment centers in Southern California," Mr. Howarth said. "With capacity and near capacity at our centers, we are reaping the success of our recent marketing efforts. Also, in this economy, we are seeing a trend away from the centers for the rich and famous and toward our facilities that provide equally excellent services at a more affordable price."

"We have 30-40 success stories every month with our 28-90 day in-patient residential, community-based treatment centers. It's an exciting and very rewarding business to be in," Forterus' CEO said in the Gaskins interview.

Mr. Howarth also said that he and Jerrod Menz, Forterus Vice President and President of its "A Better Tomorrow" facility, have recently signed employment contracts for the next five years. "I believe it sends the right message to our shareholders that we are continuing with the Company." Mr. Howarth also said the Company is initiating a buyback plan to retire some of its outstanding common shares.

"We believe in consistent, sustainable growth. We are very pleased with our shareholders who have stayed with the Company and are now gaining significant rewards," Mr. Howarth said.

For more information about Forterus and the variety of services it provides, including behavioral, intervention services, drug and alcohol rehabilitation, pain management and physical therapy, visit www.forterushealthcare.com and www.abttc.com for its "A Better Tomorrow" facility.

BLUE DIAMOND VENTURES INCORPORATED (OTC: BLDV)

"Up 250.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/BLDV.php 

Blue Diamond Ventures, Inc. is an agricultural company, and through its affiliate, Blue Diamond Ventures Biofuels, LLC, conducts business as a biofuels company with operations in the U.S. and future endeavors in the Caribbean and Ethiopia.

BLDV News:

September 2 - Blue Diamond Ventures Moves Toward Wind Turbine Agreement, Following Highly Favorable Wind Study Results

Following highly favorable wind study results in Huerfano County, Colorado, Blue Diamond Ventures, Inc. (OTC: BLDV), through its affiliate Blue Diamond Ventures Renewables, LLC, and its joint venture partner Freedom Works, LLC, have moved toward a wind turbine supply agreement and final designs to construct a 198 megawatt wind project plus 68 miles of transmission line.

On-site met tower wind data for the joint venture's Huerfano Project will be completed on September 8, 2009. The data for the project is available at:

www.engr.colostate.edu/ALP/ALP_62_Sheep_Mountain.htm.

The new study is the culmination of five years of wind data studies throughout Huerfano County and proves the existence of resource at the Colorado Wind Generation Resource Area #8 as described by the Governor's Energy Office. The project's transmission line has been identified by Colorado Governor Bill Ritter as the number one transmission priority in the State of Colorado.

"Despite the current economic environment, we have worked extremely hard to meet our goals and increase shareholder value," said Blue Diamond CEO John Quincey Moaning.

Last year, the company established a goal to implement its renewable generation portfolio — the foundation of which is the development of basic infrastructure to facilitate timely transmission, substation and wind turbine generator installations in the Midwestern United States.

POWER 3 MEDICAL PRODUCTS INCORPORATED (OTCBB: PWRM)

"Up 86.54% on Wednesday"

Detailed Quote: www.otcpicks.com/quotes/PWRM.php 

Power3 Medical Products Inc. is a leading Bio Medical company engaged in the commercialization of cancer and neurodegenerative disease biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

PWRM News:

September 2 - Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinson's Disease

On-line Publication of Biomarker Panel that Forms Basis for NuroPro®PD Diagnostic Test

Transgenomic, Inc. (OTCBB: TBIO) and Power3 Medical Products, Inc. (OTCBB: PWRM) announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker panel to distinguish Parkinson's disease (PD) patients from age-matched normal controls independent of the severity of symptoms, using clinical blood serum samples.

The analytic technology forms the basis for the NuroProPD test for PD being commercialized by Transgenomic as per a licensing/collaboration agreement with Power3 Medical signed in early 2009. The publication of the peer-reviewed article is a significant validation milestone in the ongoing clinical development of the NuroProPD diagnostic assay.

The article describes the use of analytically validated quantitative 2D gel electrophoresis to identify protein biomarkers for diagnosing PD using serum from routinely collected blood samples. 57 protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls. A multi-variate statistical method, stepwise linear discriminant analysis, selected a combination of 21 of the biomarkers as optimal to distinguish PD patients from controls. When applied to the PD samples, the 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classified, as were all 6 PD samples from an independent site.

"We are enthusiastic about the acceptance of our paper in this established peer-reviewed scientific journal. It represents independent external validation of the clinical data, and so increases the confidence that we have in NuroProPD to be a meaningful tool for the diagnosis of Parkinson's disease, especially early in its course," said Craig Tuttle, CEO of Transgenomic. "We are completing the clinical validation of the assay in our CLIA-certified molecular testing laboratory and will be launching the assay in the very near future."

"In the U.S., there are an estimated 1.5 million individuals with Parkinson's disease. Unfortunately, by the time patients are given a probable diagnosis, many have already suffered substantial and irreparable brain damage, rendering treatment less effective," said Dr. Ira Goldknopf, President and CSO of Power3 Medical and lead author on the paper. "The fact that these results were obtained using fresh blood serum, in the same way that the test will be performed in a clinical diagnostic setting, provides further support for their robustness and their commercial value."

Clinical investigators in the study were Dr. Katerina Markopoulou of the University of Thessaly, Greece, Drs. Marwan Sabbagh and Holly Shill of Banner Sun Health Research Institute, Sun City, Arizona, and Dr. Stanley Appel of the Texas Methodist Health System, Houston.

ABOUT TRANSGENOMIC, INC.

Transgenomic, Inc. (OTCBB: TBIO) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,450 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared to manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for pharmacogenomic, translational research and clinical trials.

CAVIT SCIENCES INCORPORATED (OTC: CVIT)

"Up 32.43% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CVIT.php 

Cavit Sciences, Inc. (“Cavit”) is a biotechnology company that owns a unique supplement line with products that enhance, improve, maintain and support the body by beneficially affecting various conditions. The supplement products will be showcased on this website with complete descriptions and details. In addition, the Company is engaged in developing treatments and prevention for viral infections, opportunistic infections, related diseases and the immune system. It currently owns twelve patent applications and its strategy is to develop and commercialize these intellectual property rights.

CVIT News:

September 1 - Cavit Sciences Inc. Enters Into Contracts with McCoy Enterprises LLC to Finalize Merger Agreement

Cavit Sciences Inc. (OTC: CVIT) management has been negotiating with Randall McCoy and Joe Connell principle owners of McCoy Enterprises LLC to merge our companies. Maggie Smyth, CEO of Cavit states, “We all feel very good about this fit so we have added a breakup clause to show our commitment to each other”.

“McCoy” has been working on getting final FDA approval for their Cultured Skin Substitute (PermaDerm™). Their CSS has already been given Orphan Drug Status by the FDA and will be indicated for children under 12 years old with 50% or more body surface burned.

Along with the merger agreement “Cavit” and “McCoy” are working together to secure a $16,000,000 Loan to facilitate and get final FDA approval for the first indication of “PermaDerm™” this should be accomplished in the next few days.

Maggie Smyth interim CEO of Cavit states, “This agreement to finalize our merger has been long and hard, but both sides realize that as a team we see a bright and prosperous future for the Shareholders of our Company and the patients who will benefit most from the development of “PermaDerm™”.

Joe Connell, Chief Operations Officer of McCoy, also states “We have taken all serious efforts to see that 'PermaDerm™' gets to market as fast as possible for the people that need it. As we grow and develop new indications for our CSS we see our mergered companies as a leader in Skin Cell Regeneration. We expect to have PermaDerm™ available in 2010 for its first indication.”

SYSTEMS EVOLUTION INCORPORATED (OTC: SSEV)

"Up 100.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/SSEV.php 

Systems Evolution, Inc. (SEVI), a professional services organization, provides computer software development services, computer network support, and contract staff for its clients. The company uses Microsoft and IBM Rational tools to build software and support computer networks. The company’s principal client is the State of Texas government. The company, through its subsidiary, Southwest CMS Technology Services LP and its general partner CMS Associates, LLC (CMS), provides Microsoft and Novell network integration. SEVI operates Next Hire Consultants, Inc. (Next Hire), Houston based staffing firm providing placement services to the infrastructure engineering industry. SEVI’s subsidiaries also include Duration Software, Inc. (Duration), a software development company based in Austin that provided services primarily to State of Texas departments. SERVICES The company had two distinct divisions — the Consulting Division that provides software development and managed network support services, and the Next Hire Consultants Division (NHC) that provides engineering permanent placement services. Consulting Division The company’s consulting division provides software development services using Microsoft .Net and the IBM Rational Unified Process. ‘.NET’ is the Microsoft Web services strategy integrated across the Microsoft platform, whose technology provides the ability to build, deploy, manage, and use connected, security-enhanced solutions with Web services. The IBM Rational Unified Process is an IBM copyrighted process for delivering software development services, using a software engineering implementation framework. The company’s consulting division also provides managed network support services from its network operations center in San Antonio. The company’s managed network support services provide proactive management of network servers and workstations, including application of operating system patches, analysis of available resources, analysis of hardware viability, firewall maintenance, help desk support services, and uptime service level agreements (SLA). Markets and Clients: The company, through its consulting division primarily offers its services in Houston, San Antonio, and Austin. The consulting division’s principal clients are the State of Texas and MedDorna. NHC Division The company’s NHC division provides permanent placement services, with a focus on placement of engineers in the oil & gas and public infrastructure industries. NHC offers, a managed recruiting service that provides ongoing recruiting support for its clients’ internal Human Resource departments. This service provides NHC recruiting professionals and segregated access to the company’s internal candidate database for each client. Markets and Clients: The company, through its NHC division primarily offers its services in SEVI’s Houston office. NHC’s principal clients are Staffing Technologies and Shell Oil USA, Inc. Vendor Partner Programs The company’s third party vendor partners include Microsoft and IBM Rational, each have annual partnership agreements that require vendor certified employees and partner license usage. Competition The company’s principal competitors include: regional consulting firms, such as Perficient Inc. and eLinear Solutions; national consulting firms, such as Answerthink, Inc., Accenture, BearingPoint, Inc., Ciber, Inc., Electronic Data Systems Corporation, and Sapient Corporation; and offshore providers, such as Cognizant Technology Solutions Corporation, Infosys Technologies Limited, Satyam Computer Services Limited, and Wipro Limited. History Systems Evolution, Inc. was incorporated in 1968.

SSEV News:

August 26 - Systems Evolution CEO Steven Humphries Comments on Hoss Motor Sports Acquisition

Systems Evolution, Inc. (OTC: SSEV) closed on the purchase of Hoss Motor Sports, Inc. (HMSI) this week after the Sympowerco, Inc. purchase was terminated. Hoss Motor Sports is the manufacturer of Ultimate Terrain Vehicles (UTV) and developed the first UTV for the mining industry that is used up to 2,000 feet under ground.

Chief Executive Officer Steven Humphries commented on the company, its plans and its future stating, "With the acquisition of HMSI, we will refocus our marketing efforts on the search and rescue market which will target states, municipalities and other countries in the Hurricane, Tornado and Earthquake zones around the world."

Hoss Motor Sports, Inc. has developed and designed a variety of types of Off Road Utility Vehicles including vehicles designed specifically for Search and Rescue, Construction Sites and for Sport Utility and Off Road Enthusiast markets. Under the Systems Evolution umbrella HMSI will manufacture its advanced vehicles at HMSI's new facility in Dumas, Arkansas.

HMSI Management is projecting sales in excess of $3.0M in 2010, which would represent approximately 325 units sold.

Humphries added, "This product line has unlimited potential and we are very excited to have HMSI a part of the SSEV group of companies."

VONAGE HOLDINGS CORPORATION (NYSE: VG)

"Up 19.58% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/VG.php 

Vonage Holdings Corp., through its subsidiaries, provides broadband Voice over Internet Protocol services to residential and small business and home office customers. It offers various features, such as call waiting, caller ID with name, call forwarding, and voicemail. The company also provides area code selection, number portability, online account management, and personalized Web-enabled voicemail. In addition, it offers services, including Vonage visual voicemails, virtual phone numbers, toll free numbers, and residential and business fax services, as well as Vonage SoftPhone, a software application that is downloaded and installed on computers, laptops, and WiFi-enabled personal digital assistant devices, which enables user to use a computer as a telephone. Further, the company offers Vonage-enabled devices, such as Vonage V-Portal to connect up to two Vonage lines through a high-speed Internet connection and includes a networking router; analog telephone adapters, which convert analog audio signals into digital data packets for transmission over the Internet; integrated adapters and wireless routers; Vonage Bundled Cordless Phone; V-phone, a USB compatible device; and Vonage Companion, a downloadable softphone that can be loaded on a laptop or PC. As of December 31, 2008, it had approximately 2.6 million subscriber lines in service. The company was incorporated in 2000 and is headquartered in Holmdel, New Jersey.

VG News:

September 1 - Vonage Obtains Application Approval for iTunes App Store

Vonage (NYSE: VG) has announced that Apple approved its mobile application for iPhone and iPod Touch. Vonage is currently conducting a beta test and general availability will be announced at a later date.

This new service, along with the recent launch of the Vonage World unlimited calling plan, continues Vonage's heritage of using innovative technology to create significant value for its current and future customers.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.